Development and validation of a sensitive LC-MS/MS assay for the simultaneous quantification of allitinib and its two metabolites in human plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 86, Issue , 2013, Pages 49-55

  Lin, Lishan ^a   Gao, Zhiwei ^a   Chen, Xiaoyan ^a   Zhong, Dafang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Allitinib; Human plasma; Liquid chromatography tandem mass spectrometry; Metabolite; Pharmacokinetics

Indexed keywords

29,30 DIHYDRODIOL ALLITINIB; ALLITINIB; AMIDE HYDROLYSIS METABOLITE; ANTINEOPLASTIC AGENT; AST 1306; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; SOLID TUMOR;

ALLITINIB; APCI; ATMOSPHERIC-PRESSURE CHEMICAL IONIZATION; ERBB; ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG; FDA; FOOD AND DRUG ADMINISTRATION; HUMAN PLASMA; INTERNAL STANDARD; IS; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LLOQ; LOWER LIMIT OF QUANTIFICATION; METABOLITE; MRM; MULTIPLE REACTION MONITORING; PHARMACOKINETICS; QC; QUALITY CONTROL; RE; RELATIVE ERROR; RELATIVE STANDARD DEVIATION; RSD; S/N; SIGNAL TO NOISE; ULOQ; UPPER LIMIT OF QUANTIFICATION;

ACRYLAMIDES; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; QUINAZOLINES; TANDEM MASS SPECTROMETRY;

EID: 84882988372     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.07.003     Document Type: Article

References (12)

1. Gonzales A.J., Hook K.E., Althaus I.W., Ellis P.A., Trachet E., Delaney A.M., Harvey P.J., Ellis T.A., Amato D.M., Nelson J.M., Fry D.W., Zhu T., Loi C.M., Fakhoury S.A., Schlosser K.M., Sexton K.E., Winters R.T., Reed J.E., Bridges A.J., Lettiere D.J., Baker D.A., Yang J., Lee H.T., Tecle H., Vincent P.W. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 2008, 7:1880-1889.
2. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology 1995, 19:183-232.
3. Xie H., Lin L., Tong L., Jiang Y., Zheng M., Chen Z., Jiang X., Zhang X., Ren X., Qu W., Yang Y., Wan H., Chen Y., Zuo J., Jiang H., Geng M., Ding J. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS ONE 2011, 6:e21487.
4. USFDA, 2008, (accessed 8.05.12). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079266.pdf.
5. Smith D.A., Obach R.S. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metabolism and Disposition 2005, 33:1409-1417.
6. USFDA, 2001, (accessed 28.04.13). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
7. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003, 75:3019-3030.
8. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Workshop/conference report-quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS Journal 2007, 9:E30-E42.
9. Jones H.M., Parrott N., Ohlenbusch G., Lave T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clinical Pharmacokinetics 2006, 45:1213-1226.
10. Singh B.N., Malhotra B.K. Effects of food on the clinical pharmacokinetics of anticancer agents-underlying mechanisms and implications for oral chemotherapy. Clinical Pharmacokinetics 2004, 43:1127-1156.
11. Dressman J.B. Comparison of canine and human gastrointestinal physiology. Pharmaceutical Research 1986, 3:123-131.
12. Hussein Z., Mukherjee D., Lamm J., Cavanaugh J.H., Granneman G.R. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. Journal of Clinical Pharmacology 1994, 34:754-759.